Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials

The director of the Finlay Vaccine Institute, Vicente VĂ©rez, specified on state television that the percentage has been obtained from the intermediate study of the results in the volunteers to whom two doses of Soberana 02 were applied 28 days apart.